<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2025.5.CLIN.11</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-1381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническая медицина</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical medicine</subject></subj-group></article-categories><title-group><article-title>Медико-социальные аспекты акральной меланомы кожи</article-title><trans-title-group xml:lang="en"><trans-title>Medico-social aspects of acral skin melanoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2316-7482</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Неретин</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Neretin</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Неретин Евгений Юрьевич, д-р мед. наук, врач-онколог высшей категории консультативного отделения № 1, ул. Солнечная, д. 50, г. Самара, 443029;</p><p>профессор кафедры хирургических болезней с курсом онкологии, ул. Чапаевская, д. 227, г. Самара, 443001</p></bio><bio xml:lang="en"><p>Evgeniy Yu. Neretin, Dr. Sci. (Med.), oncologist of the highest category, Advisory Department No. 1, Solnechnaya St., 50, Samara, 443029;</p><p>Professor, Department of Surgical Diseases with a Course in Oncology, Chapaevskaya St., 227, Samara, 443001</p></bio><email xlink:type="simple">evg.neretin2002@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4460-9136</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Титов</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Titov</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Титов Константин Сергеевич, д-р мед. наук, профессор, ведущий научный сотрудник, 2-й Боткинский проезд, д. 5, г. Москва, 125284;</p><p>профессор кафедры онкологии и рентгенорадиологии имени академика В.П. Харченко, ул. Миклухо-Маклая, д. 6, г. Москва, 117198</p></bio><bio xml:lang="en"><p>Konstantin S. Titov, Dr. Sci. (Med.), Professor, Leading Researcher, 2-y Botkinskiy proezd, 5, Moscow, 125284,;</p><p>Professor, Department of Oncology and Roentgenology named after Academician V.P. Kharchenko, Miklukho-Maklaya st., 6, Moscow, 117198</p></bio><email xlink:type="simple">ks-titov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-2715-3933</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якушева</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakusheva</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Якушева Татьяна Александровна, заведующая онкологическим отделением № 1 ЦАОП, </p><p>2-й Боткинский проезд, д. 5, г. Москва, 125284</p></bio><bio xml:lang="en"><p>Tat'yana A. Yakusheva, Head of the Oncology Department No. 1, Central Asian Oncology Center, </p><p>2-y Botkinskiy proezd, 5, Moscow, 125284</p></bio><email xlink:type="simple">t.a.y.2017@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Самарский областной клинический онкологический диспансер;&#13;
Медицинский университет «Реавиз»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara Regional Clinical Oncology Dispensary;&#13;
Medical University "Reaviz"</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский многопрофильный научно-клинический центр им. С.П. Боткина;&#13;
Российский университет дружбы народов имени Патриса Лумумбы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;&#13;
Patrice Lumumba Peoples' Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Московский многопрофильный научно-клинический центр им. С.П. Боткина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>01</month><year>2026</year></pub-date><volume>15</volume><issue>5</issue><fpage>106</fpage><lpage>114</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Неретин Е.Ю., Титов К.С., Якушева Т.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Неретин Е.Ю., Титов К.С., Якушева Т.А.</copyright-holder><copyright-holder xml:lang="en">Neretin E.Y., Titov K.S., Yakusheva T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/1381">https://vestnik.reaviz.ru/jour/article/view/1381</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Акральная меланома кожи является подгруппой заболеваний меланомы кожи, для которой характерно более злокачественное течение.</p><p>Целью исследования было изучение некоторых медико-социальных особенностей группы пациентов с акральной меланомой кожи.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: данные популяционного ракового регистра, амбулаторные карточки и истории болезни всей генеральной совокупности пациентов с меланомой кожи, акральной меланомой и различными доброкачественными новообразованиями кожи, прошедшие лечение в ГБУЗ СОКОД за 2000–2022 годы. Были сформированы две группы: 233 пациента с верифицированной акральной меланомой (66 мужчин, 167 женщин) и 415 пациентов с доброкачественными новообразованиями кожи. Проведён анализ анатомической локализации, факторов внутренней среды (аутоиммунные заболевания, фенотипические признаки, семейный анамнез), а также внешних социальных факторов (образование, осведомленность, инициация обращения).</p></sec><sec><title>Результаты</title><p>Результаты. Акральная меланома преимущественно поражает нижнюю конечность (71,67%), особенно ногтевую фалангу первого пальца (47,9%); среди пациентов с акральной меланомой преобладают лица с высшим образованием (42,29%) и осведомленные о признаках заболевания (45,06%); инициация обращения в большинстве случаев самостоятельная (80,63%); аутоиммунные заболевания и семейная история меланомы редки (менее 3%); преобладает светлый фенотип (блондины — 88,3%).</p></sec><sec><title>Выводы</title><p>Выводы. Акральная меланома кожи характеризуется специфической локализацией и низкой наследственной предрасположенностью; социальные факторы (образование, осведомленность) способствуют ранней диагностике, что подчёркивает необходимость усиления санитарно-просветительской работы для снижения смертности.</p></sec></abstract><trans-abstract xml:lang="en"><p>The relevance of the study lies in the fact that acral skin melanoma is a subgroup of skin melanoma diseases characterized by a more malignant course. The aim of the study was to investigate certain medico-social features of a group of patients with acral skin melanoma. The materials and methods included data from the population cancer registry, outpatient cards, and medical histories of the entire general population of patients with skin melanoma, acral melanoma, and various benign skin neoplasms who received treatment at the State Budgetary Healthcare Institution Samara Regional Clinical Oncology Dispensary (GBUZ SOKOD) from 2000 to 2022. Two groups were formed: 233 patients with verified acral melanoma (66 men, 167 women) and 415 patients with benign skin neoplasms. Analysis was conducted on anatomical localization, internal environment factors (comorbid autoimmune diseases, phenotypic traits, presence of other malignant neoplasms and melanoma in history), and external social factors (education, patient awareness of disease signs, initiator of medical consultation). Results: Acral melanoma predominantly affects the lower extremities (71.67%), especially the nail phalanx of the first toe (47.9%); among patients with acral melanoma, higher education prevails (42.29%) and awareness of melanoma signs is 45.06%; consultation initiation is mostly self-initiated (80.63%); autoimmune diseases and family history of melanoma are rare (&lt;3%); light phenotype dominates (blondes — 88.3%). Conclusions: Acral skin melanoma is characterized by specific localization and low hereditary predisposition; social factors (education, awareness) contribute to early diagnosis, emphasizing the need for enhanced health education to reduce mortality.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>меланома [D008545]</kwd><kwd>акральная меланома [D008545]</kwd><kwd>новообразования кожи [D012878]</kwd><kwd>эпидемиология [D004813]</kwd><kwd>факторы риска [D012307]</kwd><kwd>ранняя диагностика [D055088]</kwd><kwd>санитарное просвещение [D006266]</kwd><kwd>аутоиммунные заболевания [D001327]</kwd><kwd>семейный анамнез [D005192]</kwd><kwd>фенотип [D010641]</kwd></kwd-group><kwd-group xml:lang="en"><kwd>melanoma [D008545]</kwd><kwd>melanoma [D008545]</kwd><kwd>skin neoplasms [D012878]</kwd><kwd>epidemiology [D004813]</kwd><kwd>risk factors [D012307]</kwd><kwd>early diagnosis [D055088]</kwd><kwd>health education [D006266]</kwd><kwd>autoimmune diseases [D001327]</kwd><kwd>family history [D005192]</kwd><kwd>phenotype [D010641]</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed B, Qadir MI, Ghafoor S. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291-297. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020028454. PMID: 32894659.</mixed-citation><mixed-citation xml:lang="en">1 Ahmed B, Qadir MI, Ghafoor S. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291-297. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020028454. PMID: 32894659.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023 Aug 5;402(10400):485-502. https://doi.org/10.1016/S0140-6736(23)00821-8. Epub 2023 Jul 24. Erratum in: Lancet. 2023 Aug 5;402(10400):450. PMID: 37499671.</mixed-citation><mixed-citation xml:lang="en">2 Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023 Aug 5;402(10400):485-502. https://doi.org/10.1016/S0140-6736(23)00821-8. Epub 2023 Jul 24. Erratum in: Lancet. 2023 Aug 5;402(10400):450. PMID: 37499671.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther. 2022 Dec;240:108301. https://doi.org/10.1016/j.pharmthera.2022.108301. Epub 2022 Oct 23. PMID: 36283453.</mixed-citation><mixed-citation xml:lang="en">3 Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther. 2022 Dec;240:108301. https://doi.org/10.1016/j.pharmthera.2022.108301. Epub 2022 Oct 23. PMID: 36283453.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Basurto-Lozada P, Molina-Aguilar C, Castaneda-Garcia C, Vázquez-Cruz ME, Garcia-Salinas OI, Álvarez-Cano A, Martínez-Said H, Roldán-Marín R, Adams DJ, Possik PA, Robles-Espinoza CD. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2021 Jan;34(1):59-71. https://doi.org/10.1111/pcmr.12885. Epub 2020 Jun 17. PMID: 32330367; PMCID: PMC7818404.</mixed-citation><mixed-citation xml:lang="en">4 Basurto-Lozada P, Molina-Aguilar C, Castaneda-Garcia C, Vázquez-Cruz ME, Garcia-Salinas OI, Álvarez-Cano A, Martínez-Said H, Roldán-Marín R, Adams DJ, Possik PA, Robles-Espinoza CD. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2021 Jan;34(1):59-71. https://doi.org/10.1111/pcmr.12885. Epub 2020 Jun 17. PMID: 32330367; PMCID: PMC7818404.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kuchelmeister C., Schaumburg-Lever G., Garbe C. Acral cutaneous mela-noma in caucasians: clinical features, histopathology and prognosis in 112 patients. J. Dermatol. 2000;143:275–280.</mixed-citation><mixed-citation xml:lang="en">5 Kuchelmeister C., Schaumburg-Lever G., Garbe C. Acral cutaneous mela-noma in caucasians: clinical features, histopathology and prognosis in 112 patients. J. Dermatol. 2000;143:275–280.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2013:289.</mixed-citation><mixed-citation xml:lang="en">6 Chissov V.I., Starinskiy V.V., Petrova G.V. Zlokachestvennyye novoobrazovaniya v Rossii v 2011 godu (zabolevayemost′ i smertnost′). Moscow: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii. 2013:289. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Imyanitov E.N., Abysheva S.N., Iyevleva A.G., et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res. 2011;21:555–559.</mixed-citation><mixed-citation xml:lang="en">7 Imyanitov E.N., Abysheva S.N., Iyevleva A.G., et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res. 2011;21:555–559.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bernardes SS, Ferreira I, Elder DE, Nobre AB, Martínez-Said H, Adams DJ, Robles-Espinoza CD, Possik PA. More than just acral melanoma: the controversies of defining the disease. J Pathol Clin Res. 2021 Nov;7(6):531-541. https://doi.org/10.1002/cjp2.233. Epub 2021 Jul 2. PMID: 34213090; PMCID: PMC8503895.</mixed-citation><mixed-citation xml:lang="en">8 Bernardes SS, Ferreira I, Elder DE, Nobre AB, Martínez-Said H, Adams DJ, Robles-Espinoza CD, Possik PA. More than just acral melanoma: the controversies of defining the disease. J Pathol Clin Res. 2021 Nov;7(6):531-541. https://doi.org/10.1002/cjp2.233. Epub 2021 Jul 2. PMID: 34213090; PMCID: PMC8503895.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jung S, Johnson DB. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective. Oncologist. 2022 Aug 5;27(8):703-710. https://doi.org/10.1093/oncolo/oyac091. PMID: 35640549; PMCID: PMC9355814.</mixed-citation><mixed-citation xml:lang="en">9 Jung S, Johnson DB. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective. Oncologist. 2022 Aug 5;27(8):703-710. https://doi.org/10.1093/oncolo/oyac091. PMID: 35640549; PMCID: PMC9355814.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang M, Fukushima S, Sheen YS, Ramelyte E, Pacheco NC, Shi C, Liu S, Banik I, Aquino JD, Acosta MS, Levesque M, Dummer R, Liau JY, Chu CY, Shain AH, Yeh I, Bastian BC. The genetic evolution of acral melanoma. bioRxiv [Preprint]. 2023 Oct 19:2023.10.18.562802. https://doi.org/10.1101/2023.10.18.562802. PMID: 37904969; PMCID: PMC10614839.</mixed-citation><mixed-citation xml:lang="en">10 Wang M, Fukushima S, Sheen YS, Ramelyte E, Pacheco NC, Shi C, Liu S, Banik I, Aquino JD, Acosta MS, Levesque M, Dummer R, Liau JY, Chu CY, Shain AH, Yeh I, Bastian BC. The genetic evolution of acral melanoma. bioRxiv [Preprint]. 2023 Oct 19:2023.10.18.562802. https://doi.org/10.1101/2023.10.18.562802. PMID: 37904969; PMCID: PMC10614839.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Yu H, Zheng X, Ming WK, Lak YS, Tom KC, Lee A, Huang H, Chen W, Lyu J, Deng L. Deep-learning-based survival prediction of patients with lower limb melanoma. Discov Oncol. 2023 Nov 30;14(1):218. https://doi.org/10.1007/s12672-023-00823-y. PMID: 38030951; PMCID: PMC10686915.</mixed-citation><mixed-citation xml:lang="en">11 Zhang J, Yu H, Zheng X, Ming WK, Lak YS, Tom KC, Lee A, Huang H, Chen W, Lyu J, Deng L. Deep-learning-based survival prediction of patients with lower limb melanoma. Discov Oncol. 2023 Nov 30;14(1):218. https://doi.org/10.1007/s12672-023-00823-y. PMID: 38030951; PMCID: PMC10686915.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Абрамов И.С., Емельянова М.А., Рябая О.О., Краснов Г.С., Заседателев А.С., Наседкина Т.В. Соматические мутации, вносящие вклад в метастазирование акральной меланомы. Молекулярная биология. 2019;53(4):648-653. https://doi.org/10.1134/S0026898419040025</mixed-citation><mixed-citation xml:lang="en">12 Abramov I.S., Emelyanova M.A., Krasnov G.S., Zasedatelev A.S., Nasedkina T.V., Ryabaya O.O. Somatic mutations associated with metastasis in acral melanoma. Molecular Biology. 2019;53(4):648-653. (In Russ.) https://doi.org/10.1134/S0026898419040025</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol. 2021 Jun 4;12:680407. https://doi.org/10.3389/fimmu.2021.680407. PMID: 34149718; PMCID: PMC8212860.</mixed-citation><mixed-citation xml:lang="en">13 Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol. 2021 Jun 4;12:680407. https://doi.org/10.3389/fimmu.2021.680407. PMID: 34149718; PMCID: PMC8212860.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tas F, Erturk K. Limb melanomas: acral melanomas have worse survival. J Dermatolog Treat. 2021;1–8. https://doi.org/10.1080/09546634.2021.1877248</mixed-citation><mixed-citation xml:lang="en">14 Tas F, Erturk K. Limb melanomas: acral melanomas have worse survival. J Dermatolog Treat. 2021;1–8. https://doi.org/10.1080/09546634.2021.1877248</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Behbahani S, Malerba S, Samie FH. Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004–2016. Br J Dermatol. 2020;183(5):952–954. https://doi.org/10.1111/bjd.19211</mixed-citation><mixed-citation xml:lang="en">15 Behbahani S, Malerba S, Samie FH. Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004–2016. Br J Dermatol. 2020;183(5):952–954. https://doi.org/10.1111/bjd.19211</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Howard M, Xie C, Wee E, et al. Acral lentiginous melanoma: clinicopathologic and survival differences according to tumour location. Australas J Dermatol. 2020;61:312–317. https://doi.org/10.1111/ajd.13310</mixed-citation><mixed-citation xml:lang="en">16 Howard M, Xie C, Wee E, et al. Acral lentiginous melanoma: clinicopathologic and survival differences according to tumour location. Australas J Dermatol. 2020;61:312–317. https://doi.org/10.1111/ajd.13310</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ingrassia JP, Stein JA, Levine A, Liebman TN. Diagnosis and Management of Acral Pigmented Lesions. Dermatol Surg. 2023 Oct 1;49(10):926-931. https://doi.org/10.1097/DSS.0000000000003891. Epub 2023 Aug 8. PMID: 37556446</mixed-citation><mixed-citation xml:lang="en">17 Ingrassia JP, Stein JA, Levine A, Liebman TN. Diagnosis and Management of Acral Pigmented Lesions. Dermatol Surg. 2023 Oct 1;49(10):926-931. https://doi.org/10.1097/DSS.0000000000003891. Epub 2023 Aug 8. PMID: 37556446</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tognetti L, Cartocci A, Lallas A, Moscarella E, Stanganelli I, Nazzaro G, Paoli J, Fargnoli MC, Broganelli P, Kittler H, Perrot JL, Cataldo G, Cevenini G, Lo Conte S, Simone L, Cinotti E, Rubegni P. A European Multicentric Investigation of Atypical Melanocytic Skin Lesions of Palms and Soles: The iDScorePalmoPlantar Database. Diagnostics (Basel). 2024 Feb 20;14(5):460. https://doi.org/10.3390/diagnostics14050460. PMID: 38472933; PMCID: PMC10930449.</mixed-citation><mixed-citation xml:lang="en">18 Tognetti L, Cartocci A, Lallas A, Moscarella E, Stanganelli I, Nazzaro G, Paoli J, Fargnoli MC, Broganelli P, Kittler H, Perrot JL, Cataldo G, Cevenini G, Lo Conte S, Simone L, Cinotti E, Rubegni P. A European Multicentric Investigation of Atypical Melanocytic Skin Lesions of Palms and Soles: The iDScorePalmoPlantar Database. Diagnostics (Basel). 2024 Feb 20;14(5):460. https://doi.org/10.3390/diagnostics14050460. PMID: 38472933; PMCID: PMC10930449.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tognetti L, Cevenini G, Moscarella E, Cinotti E, Farnetani F, Mahlvey J, Perrot JL, Longo C, Pellacani G, Argenziano G, Fimiani M, Rubegni P. An integrated clinical-dermoscopic risk scoring system for the differentiation between early melanoma and atypical nevi: the iDScore. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2162-2170. https://doi.org/10.1111/jdv.15106. Epub 2018 Jun 28. PMID: 29888421.</mixed-citation><mixed-citation xml:lang="en">19 Tognetti L, Cevenini G, Moscarella E, Cinotti E, Farnetani F, Mahlvey J, Perrot JL, Longo C, Pellacani G, Argenziano G, Fimiani M, Rubegni P. An integrated clinical-dermoscopic risk scoring system for the differentiation between early melanoma and atypical nevi: the iDScore. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2162-2170. https://doi.org/10.1111/jdv.15106. Epub 2018 Jun 28. PMID: 29888421.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Andre J, Sass U, Theunis A. Chapter 23: Diseases of the nails. In: McKee's Pathology of the Skin, Volume 2 ( 5th edn), E Calonje, T Brenn, A Lazar, et al. (Eds). Elsevier: Edinburgh. 2019; 1129–1155.</mixed-citation><mixed-citation xml:lang="en">20 Andre J, Sass U, Theunis A. Chapter 23: Diseases of the nails. In: McKee's Pathology of the Skin, Volume 2 ( 5th edn), E Calonje, T Brenn, A Lazar, et al. (Eds). Elsevier: Edinburgh. 2019; 1129–1155.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011 Jan;38(1):25-34. https://doi.org/10.1111/j.1346-8138.2010.01174.x. PMID: 21175752.</mixed-citation><mixed-citation xml:lang="en">21 Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011 Jan;38(1):25-34. https://doi.org/10.1111/j.1346-8138.2010.01174.x. PMID: 21175752.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Darmawan CC, Jo G, Montenegro SE, Kwak Y, Cheol L, Cho KH, Mun JH. Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019 Sep;81(3):805-812. https://doi.org/10.1016/j.jaad.2019.01.081. Epub 2019 Feb 5. PMID: 30731177.</mixed-citation><mixed-citation xml:lang="en">22 Darmawan CC, Jo G, Montenegro SE, Kwak Y, Cheol L, Cho KH, Mun JH. Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019 Sep;81(3):805-812. https://doi.org/10.1016/j.jaad.2019.01.081. Epub 2019 Feb 5. PMID: 30731177.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018 Jun 27;19(8):42. https://doi.org/10.1007/s11864-018-0560-y. PMID: 29951919.</mixed-citation><mixed-citation xml:lang="en">23 Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018 Jun 27;19(8):42. https://doi.org/10.1007/s11864-018-0560-y. PMID: 29951919.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Мяснянкин М.Ю., Гафтон Г.И., Анисимов В.В., Мацко Д.Е., Имянитов Е.Н., Семилетова Ю.В. Акральная лентигинозная меланома: современное состояние проблемы. Вопросы онкологии. 2015;61(4):563-570.</mixed-citation><mixed-citation xml:lang="en">24 Myasnyankin М.Yu., Gafton G.I., Anisimov V.V., Matsko D.Е., Imyanitov Е.N., Semiletova Yu.V. Acral lentiginous melanoma: the current state of the problem. Oncology issues. 2015;61(4):563-570. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clin Exp Dermatol. 2018 Mar;43(2):117-123. https://doi.org/10.1111/ced.13323. Epub 2017 Dec 13. PMID: 29235153.</mixed-citation><mixed-citation xml:lang="en">25 Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clin Exp Dermatol. 2018 Mar;43(2):117-123. https://doi.org/10.1111/ced.13323. Epub 2017 Dec 13. PMID: 29235153.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Milham S, Stetzer D. The electronics in fluorescent bulbs and light emitting diodes (LED), rather than ultraviolet radiation, cause increased malignant melanoma incidence in indoor office workers and tanning bed users. Med Hypotheses. 2018 Jul;116:33-39. https://doi.org/10.1016/j.mehy.2018.04.013. Epub 2018 Apr 17.</mixed-citation><mixed-citation xml:lang="en">26 Milham S, Stetzer D. The electronics in fluorescent bulbs and light emitting diodes (LED), rather than ultraviolet radiation, cause increased malignant melanoma incidence in indoor office workers and tanning bed users. Med Hypotheses. 2018 Jul;116:33-39. https://doi.org/10.1016/j.mehy.2018.04.013. Epub 2018 Apr 17.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Czajkowska Z., Hall N.C., Sewitch M., Wang B., Kцrner A. The role of patient education and physician support in self-efficacy for skin self-examination among patients with melanoma. Patient EducCouns. 2017 Aug;100(8):1505-1510. https://doi.org/10.1016/j.pec.2017.02.020. Epub 2017 Feb 24</mixed-citation><mixed-citation xml:lang="en">27 Czajkowska Z., Hall N.C., Sewitch M., Wang B., Kцrner A. The role of patient education and physician support in self-efficacy for skin self-examination among patients with melanoma. Patient EducCouns. 2017 Aug;100(8):1505-1510. https://doi.org/10.1016/j.pec.2017.02.020. Epub 2017 Feb 24</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Jain N., Anderson M.J., Patel P., Blatt H., Davis L., Bierman J., McGaghie W., Brucker J.B., Martini M., Robinson J.K. Melanoma simulation model: promoting opportunistic screening and patient counseling. JAMA Dermatol. 2013 Jun;149(6):710-6. https://doi.org/10.1001/jamadermatol.2013.2882.</mixed-citation><mixed-citation xml:lang="en">28 Jain N., Anderson M.J., Patel P., Blatt H., Davis L., Bierman J., McGaghie W., Brucker J.B., Martini M., Robinson J.K. Melanoma simulation model: promoting opportunistic screening and patient counseling. JAMA Dermatol. 2013 Jun;149(6):710-6. https://doi.org/10.1001/jamadermatol.2013.2882.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, Aitken JF, Janda M. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. Value Health. 2017 Apr;20(4):593-601. https://doi.org/10.1016/j.jval.2016.12.017. Epub 2017 Feb 15.</mixed-citation><mixed-citation xml:lang="en">29 Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, Aitken JF, Janda M. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. Value Health. 2017 Apr;20(4):593-601. https://doi.org/10.1016/j.jval.2016.12.017. Epub 2017 Feb 15.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Caldarola G, Battista C., Pellicano R. Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy. Clin Ther. 2010 Jan;32(1):57- 9. https://doi.org/10.1016/j.clinthera.2010.01.011.</mixed-citation><mixed-citation xml:lang="en">30 Caldarola G, Battista C., Pellicano R. Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy. Clin Ther. 2010 Jan;32(1):57- 9. https://doi.org/10.1016/j.clinthera.2010.01.011.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dinnes, Jonathan J. Deeks, Naomi Chuchu, Lavinia Ferrante di Ruffano, Rubeta N. Matin, David R. Thomson, Kai Yuen Wong, Roger Benjamin Aldridge, Rachel Abbott, Monica Fawzy, Susan E. Bayliss, Matthew J. Grainge, Yemisi Takwoingi, Clare Davenport, Kathie Godfrey, Fiona M. Walter, Hywel C. Williams Cochrane Database Syst Rev. 2018 Dec 4;12(12):CD011902. https://doi.org/10.1002/14651858.CD011902.pub2.</mixed-citation><mixed-citation xml:lang="en">31 Dinnes, Jonathan J. Deeks, Naomi Chuchu, Lavinia Ferrante di Ruffano, Rubeta N. Matin, David R. Thomson, Kai Yuen Wong, Roger Benjamin Aldridge, Rachel Abbott, Monica Fawzy, Susan E. Bayliss, Matthew J. Grainge, Yemisi Takwoingi, Clare Davenport, Kathie Godfrey, Fiona M. Walter, Hywel C. Williams Cochrane Database Syst Rev. 2018 Dec 4;12(12):CD011902. https://doi.org/10.1002/14651858.CD011902.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Dermoscopy, With and Without Visual Inspection, for Diagnosing Melanoma in Adults Jacqueline, Cochrane Skin Cancer Diagnostic Test Accuracy Group Affiliations expand PMID: 30521682 PMCID: PMC6517096 https://doi.org/10.1002/14651858.CD011902.pub2.</mixed-citation><mixed-citation xml:lang="en">32 Dermoscopy, With and Without Visual Inspection, for Diagnosing Melanoma in Adults Jacqueline, Cochrane Skin Cancer Diagnostic Test Accuracy Group Affiliations expand PMID: 30521682 PMCID: PMC6517096 https://doi.org/10.1002/14651858.CD011902.pub2.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
